

April 20, 2016

Press Release

Company name: CYBERDYNE, INC.
Representative: Yoshiyuki Sankai, President and CEO
Code: 7779
(Mothers Section of the Tokyo Stock Exchange)
Contact: Shinji Uga, Director and CFO
(Tel. +81-29-869-9981)

Notice regarding the agreement to enter into a consigned research and development contract with AMED

As a continuation from last year, CYBERDYNE, INC. (hereafter, to be referred to as “the Company”) has decided to enter into a consigned research and development agreement with Japan Agency for Medical Research and Development (hereafter, to be referred to as “AMED”) in regards to the projects of Longevity Science, Comprehensive Research for Persons with Disabilities, Comprehensive Research and Development for Persons with Disabilities (Refer to the contents stated in “1. Name of the research project” as well as “2. Assigned roles in the research project”) as set forth below.

1. Name of the research project

Development of Communication Aid Device for Persons with Disabilities including advanced ALS patients.

2. Assigned roles in the research project

In the fiscal year ending March 31, 2017, the Company will measure the bio-electrical signal released by the patients in a severe state of ALS, muscular dystrophy and other neuro-muscular diseases as well as patients with high spinal cord injury and tetraplegia, assess the devices which could successfully interact with intention transmission apparatus (such as PCs) and prepare for production.

3. Period of consignment

From April 1, 2016 to March 31, 2017

4. Consigned research and development expenses (as planned)

JPY 10 Million

5. Future prospects

Consigned research and development expenses are planned to be posted as non-operating income for the fiscal year ending March 31, 2017. However, it will not be determined until the screening by AMED, which will take place after the conclusion of the consigned period.